Evaluation of malignancy with thyroid imaging reporting and data system (TI-RADS) in thyroid nodules with persistent nondiagnostic cytology

Hüsniye BAŞER1*, Oya TOPALOĞLU1, Şevgül FAKI1, Afra ALKAN2, Mustafa Ömer YAZICIĞLU1, Hayriye Tatlı DOĞAN1, Ibrahim KİLINGİ1, Reyhan ERSOY1, Bekir ÇAKIR2

1Department of Endocrinology and Metabolism, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey
2Department of Biostatistics, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey
3Department of General Surgery, Atatürk Education and Research Hospital, Ankara, Turkey
4Department of Pathology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey

* Correspondence: drhusniyebaser@yahoo.com.tr

Background/aim: We aimed to evaluate the utility of thyroid imaging reporting and data system (TI-RADS) in prediction of malignancy in thyroid nodules with persistent nondiagnostic (ND) cytology.

Materials and methods: A total of 246 thyroid nodules which were surgically removed and had at least two fine-needle aspirations (FNAs) with ND cytology were included in this study. Ultrasonography features and TI-RADS scores were recorded.

Results: Of 246 nodules, 218 (88.6%) had benign and 28 (11.4%) had malignant final histopathology. Frequencies of taller than wide shape, solidity, hypoechoogenicity, microcalcifications, and presence of irregular borders were similar between benign and malignant nodules (P > 0.05). The number of nodules categorized as TI-RADS 3, 4a, 4b, and 4c were 12 (4.9%), 53 (21.5%), 104 (42.3%), and 77 (31.3%), respectively. There was not any nodule in TI-RADS 5 category. Malignancy rates of categories 3, 4a, 4b, and 4c were 0%, 13.2%, 9.6%, 14.3%, respectively. No significant differences were detected in TI-RADS categories between benign and malignant nodules (P > 0.05).

Conclusion: In this study, we did not demonstrate any suspicious ultrasound (US) finding predictive for malignancy in thyroid nodules with persistent ND cytology and did not determine any difference between malignant and benign nodules regarding TI-RADS scores. Whereas, we found that thyroid nodules in 4a, 4b, and 4c TI-RADS categories had higher malignancy rates than those previously reported in ND cytology. We think that TI-RADS categories in thyroid nodules with persistent ND cytology can be helpful in treatment decision.

Key words: Nondiagnostic cytology, malignancy, thyroid imaging reporting and data system

1. Introduction

Ultrasound (US)-guided fine-needle aspiration (FNA) is considered as the gold standard, accurate, cost-effective, and safe procedure in evaluation of thyroid nodules (1,2). However, FNA provides extremely specific and sensitive test for pathologic diagnosis, it has also some diagnostic limitations such as nondiagnostic (ND), inadequate, or unsatisfactory results. The estimated rate of malignancy in ND cytology has been reported as 1%–4% in the literature, and in this setting US-guided FNA repetition is recommended (3). The incidence of ND cytology has been reported in a wide range from 3% to 36.4% (2,4–7). A thyroid nodule with ND cytology generally causes diagnostic and therapeutic dilemma.

* Correspondence: drhusniyebaser@yahoo.com.tr

Thyroid US is a widely-used, noninvasive method in the evaluation of thyroid nodules (8,9). High risk US features for malignancy are solidity, irregular borders, microcalcifications, marked hypoechoogenicity, and more tall than wide shape (8,10,11). The thyroid imaging reporting and data system (TI-RADS) is useful in risk stratification of thyroid nodules by using the number of high risk US features (12).

TI-RADS has been initially described in 2009 by two independent teams led by Horvath et al. and Park et al. (13,14). However, these systems are found as difficult to apply in daily practice. Recently, Kwak et al. presented a more convenient and simple system for TI-RADS classification based on analysis of suspicious US features (12). Thereafter, several different TI-RADS classifications have been proposed (15–17).
TI-RADS has been determined as an effective method in malignancy prediction in thyroid lesions with various cytologies (18). In the literature, there has been a few studies evaluating the scoring systems and high risk US features in malignancy prediction of nodules with ND cytology (19,20). The aim of the present study was to assess the utility of high risk US features and TI-RADS in estimation of malignancy in thyroid nodules with persistent (at least two FNAs) ND cytology.

2. Materials and methods

2.1. Study population
The medical records of 2998 patients who underwent thyroidectomy were screened from January 2007 to December 2016, retrospectively. US features, cytology, and histopathology results of 12027 nodules in 2998 patients were recorded. Of 12027 nodules, 2646 (22%) were determined as ND cytology. These 246 nodules with ≥2 ND cytologies were included in the study.

Average time between consecutive FNA procedures was at least 3 month. ND nodules with subsequent other cytologies such as benign, atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), suspicious for follicular neoplasm (SFN), suspicious for malignancy, and malignant were excluded.

Besides demographic information, preoperative thyroid function tests (serum thyrotropin (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-thyroid peroxidase antibody (anti-TPOAb), anti-thyroglobulin antibody (anti-TgAb)), suspicious US findings, presence of Hashimoto’s thyroiditis (HT), and final histopathology results (malignant/benign) were obtained from medical records. Diagnosis of HT in histopathology was based on the presence of germinal centers, diffuse lymphocytic and plasmacytic infiltration, and enlarged epithelial cells with large nuclei and eosinophilic cytoplasm (Hurthle cells).

Serum TSH, FT3, FT4, anti-TPOAb, and anti-TgAb levels were measured by chemiluminescence methods (Immulite 2000, Diagnostic Products Corp., Los Angeles, CA, USA and UniCel DXI 800, Beckman Coulter, Brea, CA). The thyroid antibody level over the upper range of normal was evaluated as positive.

Local ethical committee approval was obtained according to the ethical standards of Helsinki declaration (Approval date and number: 22nd March 2017-2017/63).

2.2. US examination
Thyroid US was performed using an Esaote color Doppler US (Model 796FDII; MAG Technology Co. Ltd., Yung-Ho City, Taipei, Taiwan) with a superficial probe (Model LA523 13–4, 5.5–12.5 MHz). US examinations were performed by one of three endocrinologists, each with expertise in thyroid US. Suspicious US features (microcalcifications, hypoekchogenicity, irregular borders, taller than wide shape, solidity) were noted retrospectively from the US reports by an investigator. The model suggested by Kwak et al. was used for determination of TI-RADS categories (12). These categories were named as follows: category 3, nodules with no suspicious US feature; category 4a, nodules with one suspicious feature; category 4b, nodules with two suspicious features; category 4c, nodules with three or four suspicious features; and finally category 5, nodules with five suspicious US features (12). A TI-RADS score was assigned to each nodule retrospectively by the same investigator evaluating the US reports who was blind to the pathology results.

2.3. Fine needle aspiration procedure
Informed consent was taken from all patients after giving information about the FNA procedure. For the blood thinner users, these medications were stopped temporarily for 5 or more days before the procedure. FNA was carried out with a 27-gauge needle and 20-mL syringe under US guidance (Logic Pro 200 GE and 7.5 MHz probe, Kyunggigo, Korea) by experienced endocrinologists. Each nodule had average 2-3 passes from different sites. Aspirated materials were expelled onto glass slides on-site. FNA samples were air-dried and stained with Giemsa stain. Cytopathologist was not on-site during the procedure. The slides were evaluated off-side. The cytologic results were reported according to the Bethesda classification. Specimens having obscuring blood or insufficient amount of follicular cells, and smears, which were overly thick or air-dried alcohol-fixed, were evaluated as ND.

2.4. Statistical analysis
All data were analyzed with SPSS 15.0 software package (SPSS Inc., Chicago, IL, USA). Descriptive statistics were defined as mean±standard deviation (SD) for normally distributed variables, median and range (min-max) for nonnormally distributed variables, and as number of cases (%) for nominal variables. Chi-square test was performed in order to investigate the differences between the groups for categorical variables. The comparisons between groups were performed by Student’s t test and Mann–Whitney U test for parametric and nonparametric variables, respectively. A P value less than 0.05 was accepted as statistically significant.

3. Results
Among 246 patients, final histopathological diagnosis was benign in 218 (88.6%) and malignant in 28 (11.4%). However, there were 57 (26.2%) male and 161 (73.8%) female in benign group, 4 (14.3%) male and 24 (85.7%) female patients were present in malignant group (P = 0.171). There was no significant difference in mean age between two groups (P = 0.068). Median TSH was significantly higher in malignant group (P = 0.014). Serum FT3 and FT4 were not statistically different between groups.
Among 28 nodules with malignant histopathology, 25 (89.3%) were a papillary thyroid carcinoma (PTC), 1 (3.6%) was a follicular thyroid carcinoma (FTC), 1 (3.6%) was a medullary thyroid carcinoma (MTC), and 1 (3.6%) was an undifferentiated thyroid carcinoma (UTC). Of 25 nodules with PTC, 10 (40%) had classical variant, 12 (48%) had follicular variant, 2 (8%) had encapsulated follicular variant, and 1 (4%) had solid variant (Table 2). No significant differences were detected in suspicious US features between benign and malignant nodules (P > 0.05) (Table 3).

Of 246 nodules with ND cytology, 12 (4.9%) were assigned as TI-RADS 3, 53 (21.5%) as TI-RADS 4a, 104 (42.3%) as TI-RADS 4b, and 77 (31.3%) as TI-RADS 4c. Thyroid nodule with TI-RADS 5 category was not detected. No malignancies were detected in the group of nodules assigned a TI-RADS 3 category. The malignancy rates of TI-RADS category 4a, 4b, and 4c nodules were 13.2% (7 of 53 nodules), 9.6% (10 of 104 nodules), and 14.3% (11 of 77 nodules), respectively (Table 4). No significant differences were detected in TI-RADS categories between benign and malignant nodules (P > 0.05) (Table 3).

### 4. Discussion

The Bethesda system was suggested in 2009 to standardize the terminology for interpreting cytology reports among pathologists and laboratories, and to eliminate diagnostic and therapeutic dilemmas. Although a small number of cytologies represent Bethesda Category I (ND), it is the most important limitation of thyroid FNA. Furthermore, ND cytology results substantially affect the management of nodules. Although, Bethesda system recommended that ND cytology should not exceed 10% of thyroid FNA, a wide range of its usage (up to 36.4%) has been reported in the literature (3,7,21–26). Due to the 1%–4% low risk of malignancy, the Bethesda system recommends repetition of US-guided FNA in nodules with ND cytologic results. This malignancy rate is similar to the 0%–3% malignancy rate of benign cytology for which clinical follow-up is recommended by the system (3). In cases with ND cytology, actual management may depend on other factors such as clinical and sonographic features of nodules. Yet, there are currently no sufficient data for the management of the nodules with persistent ND FNAs. Due to the approximately 10% approved risk of malignancy for persistent ND cytologies, surgery may be considered in these nodules (27). In the present study, the risk of malignancy was found as 11.4% (28 of 246). In our institution, 2646 (22%) of 12027 thyroid nodules had ND cytology. Of 2646 ND nodules, 246 (9.3%) had persistent ND cytologies. The high rate of

### Table 1. Demographic characteristics and baseline laboratory data of patients according to benign and malignant final histopathology.

|                      | Benign (n = 218) | Malignant (n = 28) | P     |
|----------------------|-----------------|-------------------|-------|
| Age (years)          | 51.09±11.15     | 46.64±11.83       | 0.068 |
| Sex (M/F)            | 57/161          | 4/24              | 0.171 |
| TSH (µIU/mL)         | 1.00 (0.007-9.34) | 1.50 (0.002-6.15) | 0.014 |
| fT3 (pg/mL)          | 3.20 (1.57-6.96) | 3.17 (2.14-4.39)  | 0.470 |
| fT4 (ng/dL)          | 1.14 (0.68-2.47) | 1.20 (0.70-1.67)  | 0.400 |
| Anti TPO positivity (n,%) | n = 199 | n = 25            | 0.853 |
|                      | 43 (21.6)       | 5 (20.0)          |       |
| Anti Tg positivity (n,%) | n = 192   | n = 23            | 0.187 |
|                      | 49 (25.5)       | 3 (13.0)          |       |
| Presence of HT (n,%) | 70 (32.1)       | 14 (50)           | 0.060 |

M: male, F: female, fT3: free triiodothyronine, fT4: free thyroxine, anti-TPOAb: anti-thyroid peroxidase antibody, anti-TGAb: anti-thyroglobulin antibody, HT: Hashimoto's thyroiditis in histopathology. Significant P values are given in bold.
ND cytology in our institution can be associated with different operators performing the procedure, using different aspiration techniques in the evaluation of fine-needle cytology, and different cytologists evaluating the cytologies.

Suspicious US features associated with an increased risk of malignancy are hypoechoic echogenicity, presence of irregular borders, microcalcifications, solid pattern, and taller than wide shape (28). We did not find any difference in high risk US features between malignant and benign groups in the present study. Furthermore, we did not demonstrate any suspicious US finding predictive for malignancy in thyroid nodules with persistent ND cytology. Our study population included only the operated patients with ND cytology. In these patients, we decided surgery according to the presence of suspicious US features, which might cause statistically insignificant results between groups.

Several studies are present in the literature evaluating the TI-RADS in ND cytology (19,20). Recently, Moon et al. evaluated the US features of 548 ND nodules and classified these nodules according to TI-RADS (19). In their study, the malignancy risks for categories 3 and 4a nodules were reported as 0.8% and 1.8%, respectively. Moreover, the same authors found the malignancy rates of categories 4b, 4c, and 5 nodules as 6.1%, 14.4%, and 31%, respectively (19). Yoon et al. stratified the nodules with ND cytology according to TI-RADS before and after application of the Bethesda system (20). They reported the malignancy risks in category 3, 4a, 4b, 4c, and 5 as 1.8%, 5.7%, 4.1%, 29.8%, and 16.7% for the pre-Bethesda period, and 1.6%, 3.0%, 7.1%, 16.3%, and 25.0% for the post-Bethesda period, respectively. They concluded that similar malignancy rates were found in the pre- and post-Bethesda periods (20). In the present study, no malignancies were detected in the group of nodules with TI-RADS category 3. Our malignancy risks of 4a, 4b, and 4c categories were 13.2%, 9.6%, and 14.3%, respectively. Our study is different than those of Moon et al. and Yoon et al. according to the study population. However, Moon et al. studied all of ND nodules including the ones under follow-up, Yoon et al. analyzed ND nodules on which surgery had been performed, nodules at follow-up US guided FNA that showed no significant change, and also nodules with definitive benign or malignant cytologic results at follow-up US-guided FNA (19,20). In our study, we assessed the thyroid nodules with persistent ND cytology, which were surgically removed. Nodules with consecutive benign or malignant cytology, and nodules at follow-up without operation were excluded. Thus, 100% of nodules in our study have surgically proven histologies.

In the present study, no malignancies were detected in the group of nodules assigned a TI-RADS category of 3. Due to the low risk of malignancy, it has been reported that US follow-up can be considered for thyroid nodules with ND cytology if high risk US features are not present (19). Furthermore, this study demonstrated that the malignancy rates of thyroid nodules with categories 4a, 4b, and 4c were 13.2%, 9.6% and 14.3%, respectively. Thus, in these cases, repetition of US-guided FNA should be considered (19). In the present study, malignancy risks of nodules with categories 4a and 4c are near 15% which is the cut-off for recommending surgery, so surgery can be considered for these nodules (3).

Thyrotrophin is a major regulator of thyroid hormone production by acting on thyroid follicular cells. Furthermore, TSH consists of a vital role in normal thyroid function and thyroid diseases (29,30). Recently, it has been reported that TSH has a role in thyroid malignancy development and progression, and acts like a growth factor (31,32). Elevated TSH level was found as a risk factor for thyroid malignancy (33–35). Boelaert et al. demonstrated a higher malignancy rate in patients with TSH levels between 1.0–1.7 mU/L compared to TSH levels <0.4 mU/L, and furthermore a particularly higher rate was found in patients with TSH levels more than 1.8 mU/L (35). In the present study, mean TSH level in the malignant group was found higher as compared to the benign group.

The follicular variant of PTC is the most common subtype after classical variant, constituting between 10% and 15% of all PTC cases (36,37). However, FNA is a sensitive procedure, its reported sensitivity is significantly low in follicular variant of PTC when compared to

Table 2. Distribution of histopathology results in malignant group.

|                      | Malignant (n = 28) |
|----------------------|--------------------|
| PTC (n,%)            | 25 (89.3)          |
| Classical variant    | 10 (40)            |
| Follicular variant   | 12 (48)            |
| Encapsulated follicular variant | 2 (8) |
| Solid variant        | 1 (4)              |
| FTC (n,%)            | 1 (3.6)            |
| MTC (n,%)            | 1 (3.6)            |
| UTC (n,%)            | 1 (3.6)            |

PTC: papillary thyroid carcinoma, FTC: follicular thyroid carcinoma, MTC: medullary thyroid carcinoma, UTC: undifferentiated thyroid carcinoma.

Thyrotrophin is a major regulator of thyroid hormone production by acting on thyroid follicular cells. Furthermore, TSH consists of a vital role in normal thyroid function and thyroid diseases (29,30). Recently, it has been reported that TSH has a role in thyroid malignancy development and progression, and acts like a growth factor (31,32). Elevated TSH level was found as a risk factor for thyroid malignancy (33–35). Boelaert et al. demonstrated a higher malignancy rate in patients with TSH levels between 1.0–1.7 mU/L compared to TSH levels <0.4 mU/L, and furthermore a particularly higher rate was found in patients with TSH levels more than 1.8 mU/L (35). In the present study, mean TSH level in the malignant group was found higher as compared to the benign group.

The follicular variant of PTC is the most common subtype after classical variant, constituting between 10% and 15% of all PTC cases (36,37). However, FNA is a sensitive procedure, its reported sensitivity is significantly low in follicular variant of PTC when compared to
conventional PTC (38,39). In the present study, 89.3% (25 of 28 nodules) of patients with malignancy had PTC, of which 48% was a follicular variant.

Our study had several limitations. Firstly, it has a retrospective study design, which causes difficulty in evaluating some factors. Secondly, we evaluated previous US features only in the patients who underwent thyroid surgery. However, in clinical practice, majority of the patients with ND cytology are followed-up without operation. In this study, only 9.3% of patients with ND cytology were operated, most of our patients were going to follow-up. Thus, our results should not be generalized to all of nodules with ND cytology. Thirdly, the nodules with ND cytology, which were operated also had suspicious US features. As a result, our study population had a small number of nodules with TI-RADS category 3. Fourthly, the interval between consecutive US-guided FNAs was not evaluated in our study. In the Bethesda system, for reparation of atypia, although FNA is recommended after 3 months, the optimal interval between two procedures is not described clearly. Some authors recommend further FNA within the following 6–12 months (3,23,40). In our institution, repeat FNA was generally performed at least 3 months after the previous procedure.

In conclusion, we found malignancy rate as 11.4% in thyroid nodules with persistent ND cytology. Furthermore, we did not demonstrate any suspicious US finding predictive for malignancy in thyroid nodules with persistent ND cytology and did not determine any difference between malignant and benign nodules in TI-RADS scores. In the evaluation of TI-RADS categories for all nodules with persistent ND cytologies, no malignancy was detected in TI-RADS category 3 but malignancy rate was increased to 14.3% in TI-RADS 4 category. However, there are currently no sufficient data for the management of the nodules with persistent ND, TI-RADS categories can be helpful for the clinician in the treatment decision of these nodules.

Table 3. Comparison of high risk US features and TI-RADS categories between histopathologically benign and malignant groups.

|                      | Benign (n = 218) | Malignant (n = 28) | P     |
|----------------------|------------------|-------------------|-------|
| Nodule AP diameter (mm) | 12.13±5.77      | 12.56±5.29        | 0.704 |
| Nodule T diameter (mm) | 15.48±7.64       | 14.62±7.82        | 0.583 |
| Taller than wide shape (n,%) | 35 (16.1)      | 5 (17.9)          | 0.808 |
| Solidity (n,%)         | 203 (93.1)       | 28 (100)          | 0.358 |
| Hypoechochogenicity (n,%) | 20 (9.2)        | 3 (10.7)          | 0.568 |
| Microcalcification (n,%) | 65 (29.8)       | 8 (28.6)          | 0.892 |
| Irregular border (n,%)  | 126 (57.8)       | 18 (64.3)         | 0.512 |
| TI-RADS (n, %)         |                  |                   |       |
| TI-RADS 3              | 12 (5.5)         | 0                 | 0.203 |
| TI-RADS 4a             | 46 (21.1)        | 7 (25.0)          | 0.637 |
| TI-RADS 4b             | 94 (43.1)        | 10 (35.7)         | 0.455 |
| TI-RADS 4c             | 66 (30.3)        | 11 (39.3)         | 0.333 |
| TI-RADS 5              | 0                | 0                 | -     |

AP: anteroposterior, T: transverse, TI-RADS: thyroid imaging reporting and data system.

Table 4. Histopathology results of nodules according to TI-RADS categories.

|                      | TI-RADS 3 n = 12 | TI-RADS 4a n = 53 | TI-RADS 4b n = 104 | TI-RADS 4c n = 77 | Test statistics | P     |
|----------------------|------------------|------------------|-------------------|-------------------|----------------|-------|
| Benign (n,%)         | 12 (100)         | 46 (86.8)        | 94 (90.4)         | 66 (85.7)         | 2.682          | 0.443 |
| Malignant (n,%)      | 0                | 7 (13.2)         | 10 (9.6)          | 11 (14.3)         |                |       |

TI-RADS: thyroid imaging reporting and data system.
References

1. Haider AS, Rakha EA, Dunkley C, Zaitoun AM. The impact of using defined criteria for adequacy of fine needle aspiration cytology of the thyroid in routine practice. Diagn Cytopathol 2011; 39: 81-86.

2. Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2010; 134: 450-456.

3. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid 2009; 19: 1159-1165.

4. Yoon JH, Moon HJ, Kim EK, Kwak JY. Inadequate cytology in thyroid nodules: should we repeat aspiration or follow-up? Ann Surg Oncol 2011; 18: 1282-1289.

5. Coorough N, Hudak K, Jaume JC, Buehler D, Selvaggi S, Rivas J, Sippel R, Chen H. Nondiagnostic fine-needle aspirations of the thyroid: is the risk of malignancy higher? J Surg Res 2013; 184: 746-750.

6. Hryhorczuk AL, Stephens T, Bude RO, Rubin JM, Bailey JE, Higgins EJ, Fox GA, Klein KA. Prevalence of malignancy in thyroid nodules with an initial nondiagnostic result after ultrasound guided fine needle aspiration. Ultrasound Med Biol 2012; 38: 561-567.

7. Grani G, Calvanese A, Carbotta G, D’Alessandri M, Nesca A, Bianchini M, Del Sordo M, Fumara L. Intrinsic factors affecting adequacy of thyroid nodule fine-needle aspiration cytology. Clin Endocrinol (Oxf) 2013; 78: 141-144.

8. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, Yoo HS. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 2002; 178: 687-691.

9. Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey RB Jr. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 2003; 22: 1083-1090.

10. Moon HJ, Kwak JY, Kim MJ, Son EJ, Kim EK. Can vascularity affect adequacy of thyroid nodule fine-needle aspiration cytology? Thyroid Imaging and Data System before and after application of the Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology. Clin Endocrinol (Oxf) 2015; 82: 439-444.

11. Maia FF, Matos PS, Pavin EJ, Zantut-Wittmann DE. Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with nondiagnostic results at cytologic examination: combination of thyroid imaging reporting and data system and the Bethesda system. Radiology 2015; 274: 287-295.

12. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Thyroid nodules: nondiagnostic cyto logical results according to Thyroid Imaging Reporting and Data System (TI-RADS). Clinical Endocrinology (Oxf) 2016; 85: 275-282.

13. Moon HJ, Kim EK, Yoon JH, Kwak JY. Malignancy risk stratification in thyroid nodules with nondiagnostic results at cytologic examination: combination of thyroid imaging reporting and data system and the Bethesda system. RadioLOGY 2015; 274: 287-295.

14. Park JY, Lee HJ, Jang HW, Kim HK, Yi JH, Lee W, Kim SH. A proposal for a thyroid imaging reporting and data system for ultrasound features of thyroid carcinoma. Thyroid 2009; 19: 1257-1264.

15. Russ G, Royer B, Bigorgne C, Rouxel A, Bienvenu-Perrard M, Leenhardt L. Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol 2013; 168: 649-655.

16. Choi YJ, Baek JH, Baek SH, Shim WH, Lee KD, Lee HS, Shong YK, Ha EJ, Lee JH. Web-based malignancy risk estimation for thyroid nodules using ultrasonography characteristics: development and validation of a predictive model. Thyroid 2015; 25: 1306-1312.

17. Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, Dominguez M. An ultrasound reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009; 94: 1748-1751.

18. Yoon JH, Kwon HJ, Kim EK, Moon HJ, Kwak JY. Subcategorization of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS): a study applying Thyroid Imaging Reporting and Data System (TI-RADS). Clinical Endocrinology (Oxf) 2016; 85: 275-282.

19. Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey RB Jr. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 2003; 22: 1083-1090.

20. Moon HJ, Lee HS, Kim EK, Moon HJ, Kwak JY. Thyroid nodules: nondiagnostic cyto logical results according to Thyroid Imaging Reporting and Data System before and after application of the Bethesda system. Radiology 2015; 276: 579-587.

21. Alexander EK, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Marqusee E. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87: 439-444.

22. Haider AS, Rakha EA, Dunkley C, Zaitoun AM. The impact of using defined criteria for adequacy of fine needle aspiration cytology of the thyroid in routine practice. Diagn Cytopathol 2011; 39: 81-86.

23. Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2010; 134: 450-456.

24. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid 2009; 19: 1159-1165.

25. Park JY, Lee HJ, Jang HW, Kim HK, Yi JH, Lee W, Kim SH. A proposal for a thyroid imaging reporting and data system for ultrasound features of thyroid carcinoma. Thyroid 2009; 19: 1257-1264.

26. Russ G, Royer B, Bigorgne C, Rouxel A, Bienvenu-Perrard M, Leenhardt L. Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol 2013; 168: 649-655.

27. Choi YJ, Baek JH, Baek SH, Shim WH, Lee KD, Lee HS, Shong YK, Ha EJ, Lee JH. Web-based malignancy risk estimation for thyroid nodules using ultrasonography characteristics: development and validation of a predictive model. Thyroid 2015; 25: 1306-1312.

28. Maia FF, Matos PS, Pavin EJ, Zantut-Wittmann DE. Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology. Clin Endocrinol (Oxf) 2015; 82: 439-444.

29. Yoon JH, Kwon HJ, Kim EK, Moon HJ, Kwak JY. Subcategorization of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS): a study applying Thyroid Imaging Reporting and Data System (TI-RADS). Clinical Endocrinology (Oxf) 2016; 85: 275-282.

30. Moon HJ, Kim EK, Yoon JH, Kwak JY. Malignancy risk stratification in thyroid nodules with nondiagnostic results at cytologic examination: combination of thyroid imaging reporting and data system and the Bethesda system. Radiology 2015; 274: 287-295.

31. Moon HJ, Lee HS, Kim EK, Moon HJ, Kwak JY. Thyroid nodules: nondiagnostic cyto logical results according to Thyroid Imaging Reporting and Data System before and after application of the Bethesda system. Radiology 2015; 276: 579-587.

32. Alexander EK, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Marqusee E. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87: 439-444.

33. Baier ND, Hahn PF, Gervais DA, Samir A, Halpern EF, Mueller PR, Harisinghani MG. Fine needle aspiration biopsy of thyroid nodules: experience in a cohort of 944 patients. AJR Am J Roentgenol 2009; 193: 1175-1179.

34. Baloch Z, LiVolsi VA, Jain P, Jain R, Aljada I, Mandel S, Langer JE, Gupta PK. Role of repeat fine-needle aspiration biopsy (FNAB) in the management of thyroid nodules. Diagn Cytopathol 2003; 29: 203-206.

35. Moon HJ, Kwak JY, Kim EK, Kim MJ. Ultrasoundographic characteristics predictive of nondiagnostic results for fine-needle aspiration biopsies of thyroid nodules. Ultrasound Med Biol 2011; 37: 549-555.

36. Renshaw AA. Accuracy of thyroid fine-needle aspiration using receiver operator characteristic curves. Am J Clin Pathol 2001; 116: 477-482.
26. Anderson TJ, Atalay MK, Grand DJ, Baird GL, Cronan JJ, Beland MD. Management of nodules with initially nondiagnostic results of thyroid fine-needle aspiration: can we avoid repeat biopsy? Radiology 2014; 272: 777-784.

27. McHenry CR, Walfish PG, Rosen IB. Non-diagnostic fine-needle aspiration biopsy: a dilemma in management of nodular thyroid disease. Am Surg 1993; 59: 415-419.

28. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB, Goellner JR et al. Management of thyroid nodules detected at US: Society of Radiologists in ultrasound consensus conference statement. Ultrasound Q 2006; 22: 231-238.

29. Grob F, Deladoey J, Legault L, Spigelblatt L, Fournier A, Vassart G, Van Vliet G. Autonomous adenomas caused by somatic mutations of the thyroid-stimulating hormone receptor in children. Horm Res Paediatr 2014; 81: 73-79.

30. Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomatous to Graves disease. J Clin Invest 2005; 115: 1972-1983.

31. He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri RV, Nagy R, de la Chapelle A. Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR and a novel lincRNA gene, PTCSC2. J Clin Endocrinol Metab 2015; 100: 164-172.

32. Khan MS, Pandith AA, Masoodi SR, Wani KA, Ul Hussain M, Mudassar S. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status. Endocrine 2014; 47: 449-455.

33. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009; 115: 972-980.

34. Hegedus L, Bonnema SJ, Bennedsen FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24: 102-132.

35. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006; 91: 4295-4301.

36. Kesmodel SB, Terhune KP, Canter RJ, Mandel SJ, LiVolsi VA, Baloch ZW, Frazer DL. The diagnostic dilemma of follicular variant of papillary thyroid carcinoma. Surgery 2003; 134: 1005-1012.

37. Shih SR, Shun CT, Su DH, Hsiao YL, Chang TC. Follicular variant of papillary thyroid carcinoma: Diagnostic limitations of fine needle aspiration cytology. Acta Cytol 2005; 49: 383-386.

38. Lin HS, Komisar A, Opher E, Blaugrund SM. Follicular variant of papillary carcinoma: the diagnostic limitations of preoperative fine needle aspiration and intraoperative frozen section evaluation. Laryngoscope 2000; 110: 1431-1436.

39. Miller JM, Hamburger JJ, Kini SR. The needle biopsy diagnosis of papillary thyroid carcinoma. Cancer 1981; 48: 989-993.

40. Jaume JC, Chen H. Inadequate cytology of thyroid nodules: repeat it or live with it. Indian J Surg Oncol 2011; 2: 76-77.